Molina Healthcare is a large government-sponsored managed care franchise with a strong balance sheet and a clear growth pipeline, but recent earnings have been pressured by medical cost inflation and contract churn. The report rates MOH a Buy, with upside tied to a recovery in margins and execution on Medicaid, Medicare, and Florida.
Molina Healthcare (MOH) is a focused government-sponsored managed care company with real scale, a strong contract engine, and a balance sheet that still gives it room to absorb a rough patch. The investment case is straightforward: the business remains large and strategically relevant, but earnings power has been hit hard by elevated medical costs, Medicaid redeterminations, the Virginia contract loss, and costs tied to repositioning Medicare and ramping Florida. That leaves MOH in a transition year rather than a clean growth year.
The bull case rests on three named facts. First, Molina reaffirmed 2026 guidance for about $42B of premium revenue and at least $5 of adjusted EPS after reporting Q1 2026 adjusted EPS of $2.35 on $10.172B of premium revenue. Second, management laid out a 2029 target of $64B in premium revenue and $25 in adjusted EPS at its May 8, 2026 Investor Day. Third, the company still has a large embedded growth pipeline, including the Florida Kids program that management described as a $6B run-rate revenue opportunity.
The bear case is just as concrete. Trailing revenue growth in the assembled valuation data is -4.3% YoY, earnings growth is -95% YoY, trailing P/E is 61.7, forward P/E is 43.9, 2025 free cash flow was negative, and 2025 net income fell to $472M from $1.179B in 2024. In plain English, MOH is not cheap on current earnings, and the market is being asked to underwrite a recovery before that recovery is fully visible in reported annual numbers.
For a balanced, medium-term investor, MOH looks more like a selective accumulation story than an all-clear momentum story. The business quality is better than the recent income statement, but the recent income statement is too weak to ignore. That tension supports a Buy rating only when the stock trades at a discount large enough to compensate for policy, utilization, and execution risk. That is why the fair value estimate in this report is $205.
As of Dec. 31, 2025, Molina served about 5.5M members across 21 states. By March 31, 2026, membership had moved to about 5.0M. That decline matters because Molina’s model depends on fixed per-member premium revenue spread across a large base while medical costs are managed tightly enough to protect margin.
The company’s revenue base is substantial. 2025 premium revenue was $43.052B and total revenue was $45.426B, up from $38.627B and $40.650B in 2024. Yet the same year also showed the core problem: consolidated medical care ratio rose to 91.7% from 89.1%, while net income dropped to $472M from $1.179B. Revenue kept growing, but margin got squeezed hard.
Management is led by CEO Joseph Zubretsky and CFO Mark Keim. The current strategy is not to chase every line of business equally. Molina is leaning into Medicaid scale, dual-eligible Medicare products, disciplined Marketplace participation, and selective acquisitions or contract wins that can add embedded earnings over time.
That quote matters because it captures the company’s current shape. Molina is narrowing its lane, not widening it. In managed care, focus can be an advantage, but only if pricing, rates, and medical trend stay in balance.
Medicaid is the engine room. In 2025, Medicaid generated $32.240B of premium revenue, or 75% of consolidated premium revenue according to the 10-K. Segment data in the assembled financials shows Medicaid Solutions at 74.7% of 2025 revenue, up from 79.0% in 2024 because Marketplace grew faster. This segment remains the company’s defining exposure.
The Medicaid franchise is broad, covering TANF, ABD, CHIP, Medicaid Expansion, and LTSS populations. The company’s biggest state exposures include Texas, Washington, California, and New York. In 2025, Texas represented about 18% of consolidated Medicaid premium revenue, while California and Washington each represented about 13%, and New York about 10%.
Q1 2026 Medicaid MCR was 92.0%. Management said the January 1 rate updates came in as expected and medical cost trend was modestly favorable to expectations. For full-year 2026, Molina kept Medicaid MCR guidance at 92.9%, built on 4% rate increases and 5% medical cost trend. That is a thin spread, which is typical for the business, but it leaves little room for error.
Medicare is smaller but strategically important. In 2025, Medicare premium revenue was $6.235B, or 14.5% of segment revenue in the assembled segment data. Molina is shifting this business toward dual-eligible products such as D-SNP, HIDE, and FIDE plans. Q1 2026 Medicare MCR was 89.8%, and management said the transition of MMP members into integrated products was completed at the start of the year.
The company also decided to exit the MAPD product for 2027. That decision came with pain upfront. Q1 2026 GAAP results included a $93M impairment tied to the planned MAPD exit. Still, management framed the move as strategic cleanup, not retreat. In 2025, MAPD represented about 117,000 members and about $1.566B, or 25%, of Medicare segment premium revenue. Exiting it should reduce distraction and sharpen focus on duals.
Marketplace is the smallest major segment and the most volatile. In 2025, Marketplace revenue was $4.487B, up from $2.506B in 2024. Membership at Dec. 31, 2025 was 655,000, up from 403,000 in 2024. But for 2026, management is deliberately shrinking exposure to restore margin. Q1 2026 Marketplace MCR was 84.0%, or about 79.5% adjusted for prior-year risk adjustment and CMS program integrity effects.
The Other segment remains immaterial. It includes Wisconsin LTSS consultative services and the commercial portion of the ConnectiCare acquisition. In 2025, Other contributed $90M of premium revenue in the 10-K and $177M in the assembled segment revenue data, still too small to drive the thesis.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Molina does not have a single consumer product in the way a software or device company does. Its flagship product is really its Medicaid managed care platform, especially for high-acuity and low-income populations. That platform is where the company has the most scale, the deepest state relationships, and the clearest operating history.
The Medicaid platform matters because it combines membership scale, state procurement expertise, provider network management, and actuarial pricing discipline. In 2025, Medicaid produced $32.240B of premium revenue. Even after redetermination pressure, management still expected about 4.5M Medicaid members by the end of 2026.
The next flagship growth product is Molina’s dual-eligible Medicare offering. Management repeatedly described duals as the strategic focus and said the integrated products were off to a good start in Q1 2026. This is not cosmetic repositioning. CMS integration trends and state efforts to align Medicaid and Medicare create a more favorable lane for a company built around complex populations.
Florida Kids also deserves attention as a flagship contract rather than a side project. Management said the Florida Children’s Medical Services program has a $6B run-rate revenue profile, that implementation is underway, and that the economics are attractive. This contract is a near-term cost burden and a medium-term earnings lever. In managed care, that is often how the best contracts look at the start: ugly in the setup, valuable in the harvest.
Molina’s moat is operational, not glamorous. The company competes through state contract execution, pricing discipline, care management, and the ability to manage high-acuity populations at scale. That is harder to copy than it sounds. A health plan can win a contract on paper; keeping medical trend, reserves, and compliance in line is the real test.
The 10-K says Molina achieved a 90% re-procurement win rate for Medicaid RFPs representing $14B in retained revenue and an 80% new contract win rate worth $20B in premium from 2019 to 2025. Those are strong numbers. They show the company is not just defending its turf, but still winning new business in a market where scale and credibility matter.
Management also highlighted investments in AI tools in the 10-K as part of operating enhancements. The filing specifically says Molina is deploying AI to enhance effectiveness and create efficiency. That is not enough by itself to justify a premium multiple, but it does fit the company’s practical style: use technology to improve medical cost management, payment integrity, and administrative efficiency rather than to tell a futuristic story.
Another advantage is specialization. Molina is more concentrated in government-sponsored care than diversified peers. That creates higher exposure to Medicaid rate risk, but it also creates sharper institutional knowledge in populations that are clinically and administratively complex. Management’s comments on behavioral cost management and high-acuity care in Florida reinforce that edge.
The risk is that an operational moat still depends on rates catching up to costs. A great mechanic cannot fix an engine with no oil. Molina’s edge is real, but it is not immune to bad pricing cycles.
For Molina, operations matter more than physical supply chains. The key operating inputs are provider networks, claims processing, actuarial reserving, state payment timing, and administrative cost control. This is a service business, but it runs with industrial discipline when it works well.
Q1 2026 offered a useful snapshot. Operating cash flow was $1.08B in the quarter, driven by the timing of government payments in Medicaid and Marketplace. Days in claims payable were 44, down from the prior 46 to 47 range, which management attributed to payment timing rather than reserve weakness.
Management defended reserve quality directly. CFO Mark Keim said the actuarial process and reserve position remain strong. That matters because reserve credibility is the plumbing behind every managed care story. If the reserve base is weak, reported earnings can become fiction with a short shelf life.
Administrative discipline remains decent. Q1 2026 adjusted G&A ratio was 6.9%, versus 6.3% a year earlier, while full-year 2026 G&A guidance remained about 6.4%. In 2025, Molina’s G&A ratio was 6.6% according to business context. That is still lean for a payer with this level of government-program complexity.
The parent-company cash flow picture is also important. Management said parent cash was about $213M at the end of Q1 and projected more than $600M by year-end through subsidiary dividends, while keeping regulated entities above an RBC target of $300M. That gives Molina flexibility to fund growth, manage debt, and preserve optionality.
Molina operates in large, policy-driven markets that still have structural growth even when near-term margins wobble. Medicaid managed care remains a major state budget tool, Medicare Advantage and special needs plans continue to gain relevance, and ACA Marketplace participation remains large even with subsidy sensitivity.
Industry data in the assembled context shows five firms, including Molina, account for 47% of all Medicaid managed care enrollment. That concentration cuts both ways. It confirms Molina’s scale, but it also means the company competes in a heavyweight division against Centene, UnitedHealth, Elevance, and CVS/Aetna.
Post-pandemic Medicaid redeterminations remain a central market force. KFF reported Medicaid enrollment fell 7.6% in FY 2025 and is expected to be largely flat in FY 2026 as unwinding matures. Molina’s own experience fits that backdrop. Management increased its same-store Medicaid membership decline assumption for 2026 to 6% from 2%, citing pressure in California, Illinois, New York, and Texas.
Medical cost pressure is the other defining market variable. States are dealing with higher utilization, higher acuity, and rate lag. Molina’s 2025 consolidated MCR of 91.7% and Q1 2026 MCR of 91.1% show that the pressure is not theoretical. The company is still profitable, but the spread between premium rates and medical trend remains tight.
The good news is that Molina’s Investor Day targets imply management still sees a path to regain earnings power. By 2029, the company targets $64B in premium revenue, adjusted pretax margin of 2% to 3%, consolidated MCR of 91% to 92%, and adjusted EPS of $25. Those targets are ambitious relative to 2026 guidance, but they are at least tied to a defined operating plan rather than vague optimism.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Molina’s customers are not typical retail insurance buyers. The company serves low-income families, Medicaid expansion populations, aged, blind, and disabled members, dual-eligible Medicare and Medicaid beneficiaries, and ACA Marketplace enrollees. In effect, Molina’s end users are members, but its paying customers are state Medicaid agencies, CMS, and subsidized exchange mechanisms.
That creates a customer profile with two layers. The first layer is institutional: states and federal agencies care about rate adequacy, compliance, access, and budget predictability. The second layer is member-facing: retention, care coordination, provider access, and product fit matter because churn and poor utilization patterns can wreck economics quickly.
Marketplace gives a good example of Molina’s customer discipline. In Q1 2026, Marketplace membership stood at 305,000, with 70% renewing members and a concentration in silver-tier products. Management said that profile supports greater stability and predictability after the company reduced exposure in a volatile segment.
In Medicare, the customer profile is moving toward dual-eligible members with more complex needs. That is a tougher population clinically, but it also fits Molina’s operating strengths better than general MAPD membership. In other words, the company is choosing customers it believes it can serve profitably, not just customers it can sign up.
Molina’s main competitors include Centene (CNC), CVS Health (CVS) through Aetna, Elevance Health (ELV), UnitedHealth Group (UNH), and in Medicare certain lines of competition with Humana (HUM). The company’s 10-K and industry context both make clear that competition is state-specific, contract-specific, and often brutal.
Relative to those peers, Molina is smaller and less diversified. That is a disadvantage in capital resources and business mix. It does not have the same commercial insurance buffers or vertically integrated assets that some rivals do. When Medicaid rates miss medical trend, Molina feels it more directly.
But smaller does not mean weaker everywhere. Molina’s focus gives it sharper exposure to the exact markets where it has built expertise. The company’s procurement record, multi-state Medicaid scale, and specialization in low-income and dual-eligible populations are real competitive assets. It is a specialist, not a conglomerate.
The missing piece in this report is a full peer multiple screen because the peer comparison payload failed. That means valuation has to lean more on Molina’s own multiples, analyst targets, earnings trajectory, and business quality than on a clean peer median stack. Even so, the strategic comparison is clear: Molina is a scaled Medicaid specialist trying to convert operational focus into margin recovery.
Molina is tied less to global geopolitics than to U.S. policy, state budgets, and healthcare inflation. For this company, Washington and state capitols matter more than oil tankers or export controls. The macro lens here is domestic regulation and public spending.
The biggest policy change in the assembled data is the One Big Beautiful Bill Act, signed in July 2025. Molina’s 10-K says the law requires states to establish work requirements, more frequent redeterminations, and cost sharing for Medicaid Expansion over 2027 to 2029. The company estimates a 15% to 20% reduction by 2029 on 1.2M Medicaid Expansion members, with any acuity shift expected to be modest and gradual.
The same law also affects Marketplace through tighter premium tax credit eligibility and pre-enrollment verification, with phase-in from 2026 to 2028. That is one reason Molina is cautious in Marketplace and is prioritizing margin over raw membership.
At the same time, there are supportive policy currents. CMS integration trends for dual-eligible populations support Molina’s Medicare strategy, and management said the CMS final rate notice improved from the preliminary notice. That does not erase risk, but it does support the shift toward integrated duals.
Inflation also matters through medical costs rather than through classic consumer demand. If provider rates, pharmacy costs, behavioral health costs, and long-term care expenses rise faster than state capitation updates, Molina’s margins compress. That is exactly what happened in 2025. The company’s future depends on restoring the balance between rates and trend.
An A- balance sheet gives Molina room to absorb a rough patch, even as earnings stay under pressure.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →2025 net income fell to $472M from $1.179B as the medical care ratio rose to 91.7%, showing how quickly margins can compress.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management reaffirmed 2026 guidance for about $42B in premium revenue and at least $5 of adjusted EPS after Q1 2026 adjusted EPS of $2.35.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Trailing P/E sits at 61.7 and forward P/E at 43.9, so the stock still needs a recovery to justify the current multiple.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s fair value is $205, with upside framed against a 2029 target of $64B in premium revenue and $25 in adjusted EPS.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Molina Healthcare is a classic case of a good franchise in a messy year. The company still has the traits that matter in managed care: scale in Medicaid, a strong procurement record, a sharpened Medicare strategy, disciplined Marketplace exposure, and a balance sheet that can carry it through a reset. Those are not minor strengths.
But the market is not wrong to demand proof. In 2025, net income fell to $472M, free cash flow turned negative, and margins compressed sharply. In Q1 2026, results improved enough to support guidance, not enough to declare victory. That is the distinction.
For medium-term investors, MOH is worth owning when the price leaves room for friction. The fair value estimate of $205 balances the company’s durable operating position against the reality that recovery is still in progress. This is not a stock for blind faith. It is a stock for disciplined optimism.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Molina Healthcare, Inc. (MOH) falls sharply after hours after an S&P MidCap 400 rebalance and renewed managed-care margin worries hit the stock. The move came without a fresh earnings report, suggesting trading flows and sector pressure drove the drop more than a new company-specific setback.
This week’s Q2 earnings recap showed that strong EPS results were not enough to lift every stock. ServiceNow and T-Mobile rallied on beats and upbeat growth stories, while Intel, American Express, and Tesla fell despite key business wins and management optimism.
US data painted a split picture: initial jobless claims fell to 187,000, the lowest since 1969, while the July PMI showed stronger growth and hotter price pressures. Rising Treasury and mortgage rates tightened conditions, keeping the market focused on a soft landing with a stubborn inflation problem.